when will eli lilly release retatrutide file for approval of obesity drug in 2027 Retatrutide, Eli Lilly's next generation

Among people who have not taken a GLP-1 drug, about one in five (22%) say they would be interested in taking a GLP-1 drug to lose weight, including 7% who say they would be very interested. Women are more likely than men to say they would be at least somewhat interested in taking these drugs to lose weight (27% v

Key Takeaways One chart covers everything: the retatrutide reconstitution chart below maps all six common vial sizes against every dose from 0.5mg to 12mg, in insulin syringe units

The non-GLP-1 alternatives matter for patients who cannot tolerate GLP-1s or do not meet eligibility, a unique hedge

The gut is the most sizeable endocrine organ in the body